Adjunctive gabapentin treatment of bipolar disorder

Citation
E. Vieta et al., Adjunctive gabapentin treatment of bipolar disorder, EUR PSYCHIA, 15(7), 2000, pp. 433-437
Citations number
23
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Psychiatry,"Clinical Psycology & Psychiatry
Journal title
EUROPEAN PSYCHIATRY
ISSN journal
0924-9338 → ACNP
Volume
15
Issue
7
Year of publication
2000
Pages
433 - 437
Database
ISI
SICI code
0924-9338(200011)15:7<433:AGTOBD>2.0.ZU;2-R
Abstract
Introduction - The aim of this study was to analyze the effectiveness of ga bapentin administration to bipolar patients who had an incomplete response to other mood stabilizers. Subjects and methods - Twenty-two RDC bipolar 1 and II patients were assess ed by means of the SADS and entered if they gave their consent to participa te. Ail them had suffered from frequent relapses, subsyndromal features (mo stly depressive) and incomplete response to other drugs. They all received open-label increasing doses of gabapentin until clinical response. The pati ents were assessed through the CGI-BP and a specific questionnaire at basel ine and at 12 weeks of follow-up. Results - Six out of the 22 patients dropped out for various reasons (four because of relapse, one because of side effects and one more because of poo r compliance). Eight of the 16 patients that completed the 12-week follow-u p showed at least two stages of improvement in the CGI. Using the last obse rvation-carried forward analysis, the improvement was statistically signifi cant for the depression subscale, and apparently related to social function ing, irritability and anxiety. Only one patient dropped out because of into lerance (mild rash). The mean dose of gabapentin was 1,310 mg/day. Conclusion - Gabapentin may be a useful drug for the add-on treatment of bi polar patients with poor response to other mood stabilizers. Gabapentin may improve depressive residual symptoms such as irritability, social withdraw al or anxiety. These results should be confirmed in randomized clinical tri als. (C) 2000 Editions scientifiques et medicales Elsevier SAS.